11 March 2021
Visiongain has published a new report on Aflatoxicosis Treatment Market Report to 2031: Forecasts by Treatment (Blood Transfusion, Oxygen Therapy, Antibiotics, Antihistamines, Immunosuppressant, and Others) PLUS COVID-19 Recovery Scenarios.
Global Aflatoxicosis Treatment market size is projected to reach US$ XX Million in 2021 and is expected to display strong revenue growth through to 2031.
COVID-19 Impact on Aflatoxicosis Treatment Market
The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the aflatoxicosis treatment market is anticipated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of components. Also, unpredictable and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. Hence, the overall COVID-19 impact is expected to continue to moderate for the global key players operating in the industry.
Increasing Instances of Foodborne Illness
Aflatoxins are toxic substances produced by a few types of fungi that are found naturally across the world; they can pollute food crops and stance a severe health risk to people and livestock. According to the World Health Organization (WHO), aflatoxins pose an important economic burden, triggering an estimated to be around 25% or more of the world’s food yields to be ruined annually.
Growing Awareness and Rising Spending in the Research & Development
The key factors pushing the growth of the aflatoxicosis treatment market are the prevalence of aflatoxicosis disease around the world. Besides, increased disposable income in developing countries such as India and China and rising healthcare spending are also accelerating the growth of the aflatoxicosis treatment market. Moreover, rising awareness among the population and the development of healthcare infrastructure are contributing to the target industry growth. Therefore, the rising research & development activities to develop ground-breaking and effective treatments for aflatoxicosis is fueling the target industry growth.
Expansion Opportunities in Emerging Markets
The rising food trade across the boundaries of developing markets rises the opportunity for global aflatoxicosis treatment. The growing occurrences of food-borne diseases and inappropriate hygiene & processing circumstances in the factories. Moreover, growing cases of mycotoxin outbreaks from developing countries such as Asia and Africa are likely to create lucrative opportunities for the target industry growth. These countries are frequently exposed to high levels of aflatoxins, which leads to immunotoxicity, carcinogenicity, and growth retardation in animals.
Key players operating in the global Aflatoxicosis Treatment market are Pfizer Inc., Zydus Cadilla, Glaxo Smith Kline, Sanofi, Johnson and Johnson, Abbott Laboratories, and many others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.
15 September 2022
The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.